Buddy’s Personal Miracle Drug
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1w ago
For people diagnosed with late-stage lung cancer, Edward “Buddy” Cutler’s story may serve as a beacon of hope, a clinical trial success story, and a reminder that statistics don’t dictate a person’s unique experience.   When Buddy was diagnosed with stage 4 (IV) non-small cell lung cancer (NSCLC) 12 years ago, he was determined to do whatever he needed to do to fight the disease. Chemotherapy stopped working just 18 months into his diagnosis, so he turned to clinical trials to treat his disease.   The first clinical trial that Buddy joined gave him side effects so severe that ..read more
Visit website
Fast-Tracking Innovation: The FDA’s Process for Approving New Cancer Therapies
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1w ago
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  The first anti-cancer therapy, mechlorethamine, was approved in 1949. Since then, the U.S. Food and Drug Administration (FDA) has worked to ensure that new lifesaving therapies reach those who need them most.  But what does it mean to be “FDA-approved?” Do all drugs have the same approval process? What is the FDA doing to get the newest therapies to market as quickly as possible?   The following information explains the basics of the FDA’s approval process to understand how ..read more
Visit website
Living Room Show Notes: Small Cell Lung Cancer Treatment Landscape
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
3w ago
Treatment options for people diagnosed or living with small cell lung cancer (SCLC) are constantly improving and expanding. In fact, there are more drugs in development right now than were developed in total over the last 50 years. Investments in SCLC are finally paying off, as new therapies represent hope for people living with the disease.   Dr. Jared Weiss from the University of North Caroline joined GO2’s March 2024 Lung Cancer Living Room to share the breadth of currently approved treatments for SCLC, the importance of palliative/supportive care while being treated for SCLC, a ..read more
Visit website
Ask the Experts: Am I at Greater Risk for Lung Cancer Because of Genetics?
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
3w ago
Question: I have a family history of lung cancer – both my mother and grandmother were diagnosed with the disease. Am I at greater risk for lung cancer because of genetics?     The role of genetics in determining someone’s lung cancer risk is not fully understood. While most cases of lung cancer are not related to inherited genetic risk, recent research showed that approximately 8-15% of the people who receive a lung cancer diagnosis carry hereditary mutations that are known to increase cancer risk. Genetic risk is most likely to play a role in lung cancer for people who are young, femal ..read more
Visit website
FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung cancer (NSCLC).  The approval is based on results from the ALINA study (NCT03456076). Participants with stage 1B (IB) to 3A (IIIA), ALK-positive NSCLC received 600 mg of Alecensa (alectinib) twice daily after surgery to remove the cancer. People treated with Alecensa (alectinib) had a meaningful red ..read more
Visit website
GO2 for Lung Cancer, Dana-Farber Cancer Institute, and Addario Lung Cancer Medical Institute Announce Expansion of Landmark Patient Research on Underlying Causes of Inherited Risk of Lung Cancer
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
Clinical Trial Aims to Unlock the Origins of Lung Cancer   WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), GO2’s medical research consortium, announced a major expansion of landmark research studying genetic risk for developing lung cancer.  The ORIGINS INITIATIVE is GO2’s multi-year, multi-million-dollar endeavor seeking to uncover the underlying causes of inherited risk of lung cancer. This research platform builds upon earlier nov ..read more
Visit website
Fern Halper, Ph.D., Appointed to GO2 for Lung Cancer Board of Directors
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
Brings background in data, AI, and analytics to help guide research collaboration and improved patient outcomes  WASHINGTON, April 15, 2024 —  GO2 for Lung Cancer (GO2) announced that the organization elected Fern Halper, Ph.D. to its board of directors. Halper is vice president and senior director of TDWI Research for advanced analytics. She has more than 20 years of experience in data analysis, predictive modeling, business analytics, and strategy development. Halper specializes in the technology areas of business intelligence, machine learning, AI, cloud computing, and data ..read more
Visit website
From Patient to Advocate: David’s Story
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
David lives in Arlington, VA, with his wife, Lisa, son, Ethan (6), and daughter, Liv (3). He is a passionate supporter of the Baltimore Ravens, Washington Capitals, Baltimore Orioles, and Penn Men’s Lacrosse, of which he was captain in 2007. He and his wife are in the process of formalizing The Sweat for Breath Foundation to improve the lives of those impacted by ALK positive lung cancer, like himself.  My diagnosis  Lung cancer was never on my radar. I’m young; still in my 30s. As a former Division One athlete, I’ve been active all my life and have remained active through sports an ..read more
Visit website
GO2’s 5K Walk/Run Series Welcomes the White Ribbon Project
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
We are excited to welcome the White Ribbon Project as a 2024 5K walk/run partner. Representatives from the White Ribbon Project will be on-site at our 5Ks to share their important mission and distribute white ribbons to community members who would like to help raise awareness about the disease. We started our partnership at the Dallas 5K on March 30 and welcomed the White Ribbon Project to our 5K in Sacramento on April 6.   The White Ribbon Project is a national nonprofit organization that promotes awareness about lung cancer by changing public perception of the disease. People with a c ..read more
Visit website
Ask the Experts: Women and Lung Cancer
GO2 Foundation for Lung Cancer
by Bethany Johnson (GO2 for Lung Cancer)
1M ago
Question: My daughter was just diagnosed with lung cancer at the age of 35. Her doctor told us that many young women are now getting lung cancer. Why is this?  (Answered by Dr. Narjust Florez from the Dana-Farber Cancer Institute during her appearance at the February 2024 Lung Cancer Living Room. It has been edited slightly for this use.)  Answer: Since 2018, for the first time in history younger women (roughly between the ages of 35 and 54) are getting more lung cancer than younger men, despite the perception that it is a disease that mostly effects men. This phenomenon is not only ..read more
Visit website

Follow GO2 Foundation for Lung Cancer on FeedSpot

Continue with Google
Continue with Apple
OR